NextCure Q3 2021 net loss widens to $17.9M; cash position $235.3M

NextCure, Inc.

2021-Q3 EPS reported -$1.90

Net loss of $17.9M for Q3 2021 vs $16.4M in Q3 2020, driven by higher R&D and G&A costs.
Cash, cash equivalents and marketable securities $235.3M at Sep 30, 2021, down $48.1M from Dec 31, 2020.
R&D expenses $13.6M (up from $12.7M) and G&A $4.9M (up from $4.7M) year-over-year.
Appointed Ellen G. Feigal and Anne Borgman to Board of Directors; added three new Scientific Advisory Board members.
Cash runway expected to fund operations into second half of 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.